Oxford BioDynamics has reported promising clinical study data for its new blood-based colorectal no-stool test, EpiSwitch NST. If introduced in the clinic, the test could reduce false positive test results, the company said.
Oxford BioDynamics' CRC Diagnostic Test Could Reduce Unnecessary Patient Follow-Ups
EpiSwitch NST Outperforms Competitors In Positive Predictive Values
Oxford BioDynamics' blood-based colorectal cancer diagnostic test EpiSwitch NST has shown high accuracy (81-85%) and positive predictive values (57-87%) for colorectal cancer and polyps. By reducing false positives, the test could minimize unnecessary follow-up procedures.
